

STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

1645
Docket No. #11
10907/13

In Re Application Of: R. Elghanian, et al.

Serial No.
09/928,250

Filing Date
9 August 2001

Examiner
To be assigned

Group Art Unit
1645

Invention: Use and Evaluation of a [2+2] Photocycloaddition in Immobilization of Oligonucleotides on a
Three-Dimensional Hydrogel Matrix



TO THE ASSISTANT COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.

Check applicable statement herebelow:

Statement Under 37 CFR 1.97(e)(1)

- ☒ Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Statement Under 37 CFR 1.97(e)(2)

- ☐ No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Signature

Royal N. Ronning, Jr.
Amersham Biosciences Corp
800 Centennial Avenue
Piscataway, New Jersey 08855

(732) 457-8423

Reg. No.: 32,529

Dated: September 23, 2002

RECEIVED

OCT 02 2002

TECH CENTER 1600/2900

Certificate of Mailing by First Class Mail

I certify that this document is being deposited on
September 23, 2002 with the U.S. Postal Service as first
class mail under 37 C.F.R. 1.8 and is addressed to the
Assistant Commissioner for Patents, Washington, D.C.
20231.

Signature of Person Mailing Correspondence

Melissa Leck

Typed or Printed Name of Person Mailing Correspondence

CC: